Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTPA intravesical immunotherapy versus pirarubicin after TURBT for recurrence prevention in non-muscle invasive bladder cancer
ChiCTR-IPR-15005891Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Jan 2015
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pseudomonas aeruginosa injection in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Recurrence rate. Started Jan 2015; status: recruiting.
02
Drugs
pseudomonas aeruginosa injection
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR-IPR-15005891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005891.